ClinicalTrials.gg
CompletedNCT04044001Updated Aug 31, 2026Results posted

BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)

A Phase 1/2 interventional study of BTZ-043 and Rifafour e-275® in Pulmonary Tuberculoses and Other Specified Pulmonary Tuberculosis, sponsored by Michael Hoelscher. Completed at 2 sites in South Africa. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Michael Hoelscher · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies in Tuberculosis, Pulmonary with a site in South Africa — 10 open to participants now, 13 under way, 3 of them phase 3. Tuberculosis, Pulmonary · South Africa.

Enrollment
50th of 67
78 · median 122
Started
2019
with 3 others
Phase 1/2
2 of 78
none open now
Registered
37th of 78
by date
Lead sponsor
6 of 78
Michael Hoelscher

Among the 78 studies in Tuberculosis, Pulmonary with a site in South Africa, this one is the 50th largest by enrollment of the 67 interventional ones that give a count, is one of 4 that started in 2019, is one of 2 in phase 1/2, and was the 37th registered.

Tuberculosis, Pulmonary

320 studies on the registry are indexed under Tuberculosis, Pulmonary; 72 are open to participants now.

Browse Tuberculosis, Pulmonary studies →

Open to participants now

10 of the 78 studies in Tuberculosis, Pulmonary with a site in South Africa are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →

Who these studies take

Of the 47 Tuberculosis, Pulmonary studies recruiting now, 22 (47%) set no upper age limit and 21 (45%) stop at 75 or younger; 12 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Tuberculosis, Pulmonary with a site in South Africa, or all of them as a file.
02

Study summary

This is a prospective, open label, two-centre, randomized, controlled, two-stage, phase Ib/IIa study to evaluate the safety, tolerability, PK, drug-drug interaction and bactericidal activity of BTZ-043 administered orally once daily over 14 days to participants with newly diagnosed, uncomplicated, smear-positive, drug-susceptible pulmonary tuberculosis.

The primary objective is to assess the safety and tolerability of BTZ-043 given over 14 days by evaluation of adverse events during treatment and follow-up period in patients with newly diagnosed, uncomplicated, smear-positive, drug-susceptible pulmonary tuberculosis.

Read the detailed description

This is a prospective, open label, two-centre, randomized, controlled, two-stage, phase Ib/IIa study to evaluate the safety, tolerability, PK, drug-drug interaction and bactericidal activity of BTZ-043 administered orally once daily over 14 days to participants with newly diagnosed, uncomplicated, smear-positive, drug-susceptible pulmonary tuberculosis:

Stage 1 is an escalating dose design in up to eight cohorts receiving different doses of BTZ-043 to define a safe dose corridor for BTZ-043. The focus of this stage is on adverse events, PK and a food-effect PK-evaluation .

Stage 2 is a parallel group comparison of 4 arms receiving different treatment regimens: three arms to receive BTZ-043 in different doses within the safe corridor defined in stage 1, compared to one arm receiving Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol as a control. This stage is focusing on adverse effects, early bactericidal activity (EBA), PK and an evaluation of PK drug-drug interaction potential.

A total of up to 77 male and female patients, aged ≥ 18 - 64 years, with newly diagnosed, smear positive, drug sensitive pulmonary tuberculosis will be enrolled.

Allocation of patients will be carried out in two stages:

Stage 1: for each cohort 3 patients will be enrolled, treated and followed-up accordingly, starting with cohort 1. In a Trial Steering Committee (TSC) meeting, decision will be made on the dose in the next cohort.

Dose escalation steps to be followed, if no safety concerns arise:

  • Cohort 1: patients to receive 250 mg BTZ-043
  • Cohort 2: patients to receive 500 mg BTZ-043
  • Cohort 3: patients to receive 750 mg BTZ-043
  • Cohort 4: patients to receive 1000 mg BTZ-043
  • Cohort 5: patients to receive 1250 mg BTZ-043
  • Cohort 6: patients to receive 1500 mg BTZ-043
  • Cohort 7: patients to receive 1750 mg BTZ-043
  • Cohort 8: patients to receive 2000 mg BTZ-043

Patients receiving the investigational drug in cohorts 1 - 8 will take BTZ-043 in fasting state for 13 days and after a pre-defined high-fat, high-caloric meal on day 14.

After all patients of a current cohort have completed at least 7 days of dosing, the TSC, composed of the national principal investigator (PI), the trial statistician, the sponsor representative and two independent scientists, will review safety data, including clinical, lab and electrocardiography (ECG) data, to assess whether dose limiting toxicity of BTZ-043, as defined below, has been observed in any participant. Depending on the outcome, the TSC will then decide on dose escalation, or on enrolling more participants to the same or a lower dose in the following cohort, according to dose escalation and stopping rules.

After the end of stage 1, the TSC will decide which of the BTZ-043 doses, which are deemed to not exceed the acceptable toxicity level, are to be moved to stage 2.

Stage 2: after the highest possible dose of the investigational drug, that has proven to be safe within the 1st stage, is identified, all remaining patients will be recruited and randomised to receive one of three different doses of BTZ-043 or to control treatment with Rifafour e-275® at a ratio of 3:3:3:2 favouring the experimental treatment.

Stage 2 is focusing on adverse effects, early bactericidal activity (EBA), PK and an evaluation of PK drug-drug interaction potential.

Allocation of patients:

  • Arm 1: patients to receive BTZ-043 in a higher dose
  • Arm 2: patients to receive BTZ-043 in a medium dose
  • Arm 3: patients to receive BTZ-043 in a lower dose
  • Control Arm 4: patients to receive Rifafour e-275® as control treatment

Participants will take in BTZ-043 in either fasted or fed state, depending on which state has shown to lead to higher exposure during the 1st stage.

Additional measurements in the 2nd stage in BTZ-arms 1 to 3 only:

  • Drug-drug interactions will be investigated: patients, who have been randomized to BTZ-043 arms, will additionally be randomized to receive either a probe drug cocktail, with drugs specifically metabolized by certain enzymes, or dolutegravir at a ratio of 2:1. Probe drugs or Dolutegravir (DTG) will be given pre-BTZ on day 0 and on day 14.

After the course of study drugs is completed (on day 14), all patients (in stage 1 and stage 2) will be referred to a government clinic to complete their course of tuberculosis (TB) according to national standards for a total of 6 months of first-line therapy.

03

Conditions studied

  • Pulmonary Tuberculoses
  • Other Specified Pulmonary Tuberculosis

Keywords

  • Tuberculosis, Pulmonary
  • Randomized Controlled Trial (RCT)
  • BTZ-043
  • Tuberculosis
  • Antitubercular Agents
  • Gram-positive Bacterial Infections
  • Escalating dose
  • Drug-sensitive TB
  • Early Bactericidal Activity (EBA)
  • Drug-drug-interaction
  • Pharmacokinetics (PK)
  • Safety
  • Tolerability
  • Bactericidal Activity
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

General inclusion criteria:

  1. Provide written, prior to all trial-related procedures including testing.
  2. Understand and willing to comply with the study procedures.
  3. Male or female adults, aged 18 up to and including 64 years.
  4. Body weight ≥ 40 kg.
  5. Participants are either unable to conceive/father children AND/OR they will be using two effective methods of , including methods used by the patient's sexual partner(s). At least one to be a barrier method.

    Disease-specific inclusion criteria:

  6. Newly diagnosed, previously untreated, drug-susceptible pulmonary TB
  7. Chest X-ray which is consistent with TB
  8. Ability to produce an adequate volume of sputum (at least 10ml estimated overnight production)
  9. ≥ 1 sputum sample from concentrated sputum positive for acid-fast bacilli on microscopy (at least 1+ on the International Union Against Tuberculosis and Lung Disease/World Health Organization (IUATLD/WHO) scale) from either a spot sputum or overnight sputum sample.

General exclusion criteria:

  1. Poor general condition, where delay in treatment cannot be tolerated or death within three months is likely, as assessed by the investigator.
  2. The patient is pregnant or breast-feeding.

    Disease-specific exclusion criteria:

  3. The patient is infected with HIV.
  4. The patient has a known intolerance to any of the study drugs or concomitant disorders or conditions for which study drugs or standard TB treatment are .
  5. Treatment with any other drug within 1 month prior to enrolment or enrolment into other clinical (intervention) trials during participation.
  6. The patient has a history of or current evidence of cardiovascular metabolic, gastrointestinal, neurological, psychiatric or endocrine diseases, or any other condition, that will influence treatment response, study adherence or survival in the judgement of the investigator, especially:

    1. Clinically significant evidence of severe TB (e.g. miliary TB, TB meningitis, excluding limited lymph node involvement)
    2. Serious lung conditions other than TB or significant respiratory impairment in the discretion of the investigator
    3. Neuropathy, epilepsy or significant psychiatric disorder
    4. Any diabetes mellitus
    5. Cardiovascular disease, such as myocardial infarction, heart failure, coronary heart disease, arrhythmia, tachyarrhythmia, or pulmonary hypertension
    6. Current or history of hypertension (systolic blood pressure >135 mmHg and/or diastolic blood pressure of >85 mmHg) AND/OR ever received antihypertensive treatment)
    7. Long syndrome or family history of long QT syndrome or sudden death of unknown or cardiac-related cause
    8. Alcohol or other drug abuse, that is sufficient to significantly compromise the safety or cooperation of the patient, includes substances prohibited by the protocol, or has led to significant organ damage, at the discretion of the investigator

    Laboratory exclusion criteria at screening:

  7. Serum amino aspartate transferase () and/or alanine aminotransferase (ALT) activity >2x the (ULN)
  8. serum alkaline phosphatase (ALP) or y-glutamyl transferase (GGT) > 2x the ULN
  9. serum total level >1.5 times the ULN
  10. estimated (eCrCl) using the Cockcroft and Gault formula level lower than 60 mls/min
  11. level \<8.0 g/dL
  12. count \<100,000/mm3
  13. serum potassium below the lower level of normal (LLN) for the laboratory

    -specific exclusion criteria:

  14. corrected QT interval (QTc)F of > 450 milliseconds (ms)
  15. Atrioventricular (AV) block with PR interval > 200 ms
  16. QRS complex > 120 ms
  17. any other changes in the ECG that are clinically relevant as per discretion of the investigator

    Restricted medication:

  18. Treatment with drugs active against Mycobacterium Tuberculosis (MTB) within the last 3 months prior to screening
  19. Requires medication as included in the following drug classes within 2 weeks prior to the first dose of study treatment:

    • medication that prolongs the QTc interval
    • Cytochrome P450 (CYP450) inhibitors or inducers, including grapefruit containing foods / beverages and St. John's Wort
    • Antacids or antipeptic drugs (antacids, H2 blockers, proton pump inhibitors)
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Outcomes assessor)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    Stage 1 - Cohort 1 (BTZ 250)

    Patients will receive 1 tablet of BTZ-043 orally once daily, containing 250mg BTZ-043 from Day 1 through to Day 14

    Drug: BTZ-043

  • Experimental
    Stage 1 - Cohort 2 (BTZ 500)

    Patients will receive 2 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (500 mg in total) from Day 1 through to Day 14

    Drug: BTZ-043

  • Experimental
    Stage 1 - Cohort 3 (BTZ 750)

    Patients will receive 3 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (750 mg in total) from Day 1 through to Day 14

    Drug: BTZ-043

  • Experimental
    Stage 1 - Cohort 4 (BTZ 1000)

    Patients will receive 4 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (1000 mg in total) from Day 1 through to Day 14

    Drug: BTZ-043

  • Experimental
    Stage 1 - Cohort 5 (BTZ 1250)

    Patients will receive 5 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (1250 mg in total) from Day 1 through to Day 14

    Drug: BTZ-043

  • Experimental
    Stage 1 - Cohort 6 (BTZ 1500)

    Patients will receive 6 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (1500 mg in total) from Day 1 through to Day 14

    Drug: BTZ-043

  • Experimental
    Stage 1 - Cohort 7 (BTZ 1750)

    Patients will receive 7 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (1750 mg in total) from Day 1 through to Day 14

    Drug: BTZ-043

  • Experimental
    Stage 1 - Cohort 8 (BTZ 2000)

    Patients will receive 8 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (2000 total) from Day 1 through to Day 14

    Drug: BTZ-043

  • Experimental
    Stage 2 - Arm 1 (BTZ high)

    Patients will receive a higher dose of BTZ-043, that has proven to be safe in stage 1 orally once daily from Day 1 through to Day 14. The dose of BTZ-043 will be determined after review of safety data from stage 1.

    Drug: BTZ-043 · Drug: Probe Drug Cocktail · Drug: Dolutegravir 50mg Tab

  • Experimental
    Stage 2 - Arm 2 (BTZ medium)

    Patients will receive a medium dose of BTZ-043, that has proven to be safe in stage 1 orally once daily from Day 1 through to Day 14. The dose of BTZ-043 will be determined after review of safety data from stage 1.

    Drug: BTZ-043 · Drug: Probe Drug Cocktail · Drug: Dolutegravir 50mg Tab

  • Experimental
    Stage 2 - Arm 3 (BTZ low)

    Patients will receive a lower dose of BTZ-043, that has proven to be safe in stage 1 orally once daily from Day 1 through to Day 14. The dose of BTZ-043 will be determined after review of safety data from stage 1.

    Drug: BTZ-043 · Drug: Probe Drug Cocktail · Drug: Dolutegravir 50mg Tab

  • Active comparator
    Stage 2 - Arm 4 (control)

    Patients will receive a standard dose of Rifafour e-275® orally once daily according to body weight from Day 1 through to Day 14. Each tablet of Rifafour e-275® contains 150mg rifampicin, 75mg isoniazid, 400mg pyrazinamide and 275mg ethambutol. The daily doses will be given to fasting patients, in accordance with South African Guidelines for treatment of TB. The total number of tablets will be based on the body weight at screening: * participants weighing 38 - 54 kg: 3 tablets * participants weighing 55 - 70 kg: 4 tablets * participants weighing \>70 kg: 5 tablets

    Drug: Rifafour e-275®

Interventions

  • BTZ-043 (250mg per tablet)

  • DrugRifafour e-275®

    Drug pages: IsoniazidStudies of IsoniazidIsoniazid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · RifampinStudies of RifampinRifampin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PyrazinamideStudies of PyrazinamidePyrazinamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · EthambutolStudies of EthambutolEthambutol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Rifafour e-275® (150mg rifampicin, 75mg isoniazid, 400mg pyrazinamide, 275 mg ethambutol per tablet)

    Also known as: Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE)

  • DrugProbe Drug Cocktail

    A probe drug cocktail will be given to randomly selected patients after inclusion on Day 1 and on Day 14 once orally. The probe drug cocktail consists of * Caffeine: 1 tablet à 150mg * Tolbutamide: 1/4 tablet à 500mg * Dextromethorphan: 10 ml syrup à 15mg/5ml * Midazolam:2 ml solution à 5mg/5ml * Digoxin: 2 tablets à 0.25mg

  • DrugDolutegravirStudies of DolutegravirDolutegravir pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1 tablet à 50mg Dolutegravir will be given to randomly selected patients after inclusion on Day 1 and on Day 14 once orally.

    Also known as: Tivicay®

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability of BTZ-043

    Safety and tolerability of BTZ-043 was assessed by evaluation of Adverse Events (AEs) during treatment- and follow-up phase (Clinical observations, Vital signs, Serum chemistry, hematology and coagulation parameters with baseline measurements. Electrocardiography (ECG), including heart rate, PR interval, QRS, QT interval, QTcF; change of QTcF from baseline; morphological abnormalities).

    Time frame: Day 1 to Day 22

Secondary outcomes

  1. Bactericidal Activity Endpoint - MGIT Time to Positivity (log10 (h))

    Liquid culture is inoculated with overnight sputum of the participants. Upon growth of Mycobacteria, the color of the medium is changing due to changes in pH. This is measured photometric and the time of the change in color is recorded. The more bactera are inoculated, the quicker the change ind color and the time to positivity. Overnight sputum is collected on Day -1, Day 0, Day 2, Day 3, Day 4, Day 6, Day 8, Day 11 and Day 14 to be able to follow the decrease in bacterial load over time.

    Time frame: Day -1 to Day 14. Change from Day -1 to Day 2, Day 2 - Day 14 and Day -1 to Day 14 have been assessed.

  2. Bactericidal Activity Endpoint - CFU

    Overnight sputum was plated on solid medium. Decrease in log 10 CFU (No. of colony forming untis) over time was assessed. Overnight sputum is collected on Day -1, Day 0, Day 2, Day 3, Day 4, Day 6, Day 8, Day 11 and Day 14 to be able to follow the decrease in bacterial load over time.

    Time frame: Day -1 to Day 14. Change from Day -1 to Day 2, Day 2 - Day 14 and Day -1 to Day 14 have been assessed.

07

Results

Posted Aug 31, 2026

Participant flow

Patients were recruited from the local TB clinics, informed and consented. With the signature of the ICF, the participants were subject to screening (up to 8 days). If participant proved to be eligible, participant was allocated (stage1) or randomized (stage 2) to treatment. One participant in stage 2 was randomized but experienced an SAE before the first administration of study medication, was withdrawn from the study and replaced. This led to enrolment of 78 p. but ony 77 were started on IMP

Participant flow — Overall Study
MilestoneStage 1 - Cohort 1 (BTZ 250)Stage 1 - Cohort 2 (BTZ 500)Stage 1 - Cohort 3 (BTZ 750)Stage 1 - Cohort 4 (BTZ 1000)Stage 1 - Cohort 5 (BTZ 1250)Stage 1 - Cohort 6 (BTZ 1500)Stage 1 - Cohort 7 (BTZ 1750)Stage 1 - Cohort 8 (BTZ 2000)Stage 2 - Arm 1 (BTZ High)Stage 2 - Arm 2 (BTZ Medium)Stage 2 - Arm 3 (BTZ Low)Stage 2 - Arm 4 (Control)
Started333333601613159
Completed333133301511137
Not completed000200301222
Withdrew: Withdrawal by subject000200301201
Withdrew: Adverse event000000000010
Withdrew: Covid19 infection000000000011

Outcome measures

PrimarySafety and Tolerability of BTZ-043

Safety and tolerability of BTZ-043 was assessed by evaluation of Adverse Events (AEs) during treatment- and follow-up phase (Clinical observations, Vital signs, Serum chemistry, hematology and coagulation parameters with baseline measurements. Electrocardiography (ECG), including heart rate, PR interval, QRS, QT interval, QTcF; change of QTcF from baseline; morphological abnormalities).

Time frame:
Day 1 to Day 22
Reported as:
Number · Adverse Event
Safety and Tolerability of BTZ-043
Adverse EventStage 1 - Cohort 1 (BTZ 250)Stage 1 - Cohort 2 (BTZ 500)Stage 1 - Cohort 3 (BTZ 750)Stage 1 - Cohort 4 (BTZ 1000)Stage 1 - Cohort 5 (BTZ 1250)Stage 1 - Cohort 6 (BTZ 1500)Stage 1 - Cohort 7 (BTZ 1750)Stage 1 - Cohort 8 (BTZ 2000)Stage 2 - Arm 1 (BTZ High)Stage 2 - Arm 2 (BTZ Medium)Stage 2 - Arm 3 (BTZ Low)Stage 2 - Arm 4 (Control)
Safety and Tolerability of BTZ-04331734151014—3517219
SecondaryBactericidal Activity Endpoint - MGIT Time to Positivity (log10 (h))

Liquid culture is inoculated with overnight sputum of the participants. Upon growth of Mycobacteria, the color of the medium is changing due to changes in pH. This is measured photometric and the time of the change in color is recorded. The more bactera are inoculated, the quicker the change ind color and the time to positivity. Overnight sputum is collected on Day -1, Day 0, Day 2, Day 3, Day 4, Day 6, Day 8, Day 11 and Day 14 to be able to follow the decrease in bacterial load over time.

Time frame:
Day -1 to Day 14. Change from Day -1 to Day 2, Day 2 - Day 14 and Day -1 to Day 14 have been assessed.
Reported as:
Mean · log(10) TTP (hrs) day 14 ch.f.baseline
Bactericidal Activity Endpoint - MGIT Time to Positivity (log10 (h))
log(10) TTP (hrs) day 14 ch.f.baselineStage 1 - Cohort 1 (BTZ 250)Stage 1 - Cohort 2 (BTZ 500)Stage 1 - Cohort 3 (BTZ 750)Stage 1 - Cohort 4 (BTZ 1000)Stage 1 - Cohort 5 (BTZ 1250)Stage 1 - Cohort 6 (BTZ 1500)Stage 1 - Cohort 7 (BTZ 1750)Stage 1 - Cohort 8 (BTZ 2000)Stage 2 - Arm 1 (BTZ High)Stage 2 - Arm 2 (BTZ Medium)Stage 2 - Arm 3 (BTZ Low)Stage 2 - Arm 4 (Control)
Bactericidal Activity Endpoint - MGIT Time to Positivity (log10 (h))0.09 ± 0.100.22 ± 0.070.27 ± 0.170.240.18 ± 0.160.37 ± 0.160.25 ± 0.09—0.17 ± 0.120.25 ± 0.080.20 ± 0.140.42 ± 0.10
SecondaryBactericidal Activity Endpoint - CFU

Overnight sputum was plated on solid medium. Decrease in log 10 CFU (No. of colony forming untis) over time was assessed. Overnight sputum is collected on Day -1, Day 0, Day 2, Day 3, Day 4, Day 6, Day 8, Day 11 and Day 14 to be able to follow the decrease in bacterial load over time.

Time frame:
Day -1 to Day 14. Change from Day -1 to Day 2, Day 2 - Day 14 and Day -1 to Day 14 have been assessed.
Reported as:
Mean · log(10)CFU/mL day 14 ch.f.baseline
Bactericidal Activity Endpoint - CFU
log(10)CFU/mL day 14 ch.f.baselineStage 1 - Cohort 1 (BTZ 250)Stage 1 - Cohort 2 (BTZ 500)Stage 1 - Cohort 3 (BTZ 750)Stage 1 - Cohort 4 (BTZ 1000)Stage 1 - Cohort 5 (BTZ 1250)Stage 1 - Cohort 6 (BTZ 1500)Stage 1 - Cohort 7 (BTZ 1750)Stage 1 - Cohort 8 (BTZ 2000)Stage 2 - Arm 1 (BTZ High)Stage 2 - Arm 2 (BTZ Medium)Stage 2 - Arm 3 (BTZ Low)Stage 2 - Arm 4 (Control)
Bactericidal Activity Endpoint - CFU-0.42 ± 0.76-1.34 ± 0.27-1.29 ± 0.52-1.08-1.63 ± 0.63-2.22 ± 1.18-0.96 ± 1.24—-2.09 ± 1.27-1.78 ± 0.85-1.48 ± 1.42-2.66 ± 0.91

Adverse events

Collected over From the beginning of screening (day -8) to the first administration of study drug (stage 1: Day 1) or probe drug administration (stage 2: Day 0), all symptoms etc. have been recorded as medical history. Adverse events were recorded from the first administration of study drug (stage 1) or probe drug (stage 2) until the follow-up visit on Day 22.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Stage 1 - Cohort 1 (BTZ 250)0/3 (0%)0/3 (0%)3/3 (100%)
Stage 1 - Cohort 2 (BTZ 500)0/3 (0%)0/3 (0%)3/3 (100%)
Stage 1 - Cohort 3 (BTZ 750)0/3 (0%)0/3 (0%)1/3 (33.3%)
Stage 1 - Cohort 4 (BTZ 1000)0/3 (0%)0/3 (0%)2/3 (66.7%)
Stage 1 - Cohort 5 (BTZ 1250)0/3 (0%)0/3 (0%)3/3 (100%)
Stage 1 - Cohort 6 (BTZ 1500)0/3 (0%)0/3 (0%)3/3 (100%)
Stage 1 - Cohort 7 (BTZ 1750)0/6 (0%)1/6 (16.7%)6/6 (100%)
Stage 1 - Cohort 8 (BTZ 2000)———
Stage 2 - Arm 1 (BTZ High)0/16 (0%)1/16 (6.3%)13/16 (81.3%)
Stage 2 - Arm 2 (BTZ Medium)1/14 (7.1%)1/14 (7.1%)10/14 (71.4%)
Stage 2 - Arm 3 (BTZ Low)0/15 (0%)1/15 (6.7%)11/15 (73.3%)
Stage 2 - Arm 4 (Control)0/9 (0%)0/9 (0%)6/9 (66.7%)
Most frequent serious events
Most frequent serious events
EventStage 1 - Cohort 1 (BTZ 250)Stage 1 - Cohort 2 (BTZ 500)Stage 1 - Cohort 3 (BTZ 750)Stage 1 - Cohort 4 (BTZ 1000)Stage 1 - Cohort 5 (BTZ 1250)Stage 1 - Cohort 6 (BTZ 1500)Stage 1 - Cohort 7 (BTZ 1750)Stage 1 - Cohort 8 (BTZ 2000)Stage 2 - Arm 1 (BTZ High)Stage 2 - Arm 2 (BTZ Medium)Stage 2 - Arm 3 (BTZ Low)Stage 2 - Arm 4 (Control)
HaemoptysisRespiratory, thoracic and mediastinal disorders——————1/6—0/160/140/15—
Pulmonary embolismRespiratory, thoracic and mediastinal disorders——————0/6—0/161/140/150/9
Pulmonary tuberculosisInfections and infestations——————0/6—0/160/141/15—
Pulmonary embolismRespiratory, thoracic and mediastinal disorders——————0/6—1/160/140/150/9
Most frequent other events
Showing 10 of 66
Most frequent other events
EventStage 1 - Cohort 1 (BTZ 250)Stage 1 - Cohort 2 (BTZ 500)Stage 1 - Cohort 3 (BTZ 750)Stage 1 - Cohort 4 (BTZ 1000)Stage 1 - Cohort 5 (BTZ 1250)Stage 1 - Cohort 6 (BTZ 1500)Stage 1 - Cohort 7 (BTZ 1750)Stage 1 - Cohort 8 (BTZ 2000)Stage 2 - Arm 1 (BTZ High)Stage 2 - Arm 2 (BTZ Medium)Stage 2 - Arm 3 (BTZ Low)Stage 2 - Arm 4 (Control)
NauseaGastrointestinal disorders0/31/30/30/32/33/31/6—1/161/140/151/9
Conjunctiva IrritationEye disorders2/30/30/30/30/30/30/6—1/160/141/151/9
DizzinessNervous system disorders0/30/31/30/31/32/30/6—5/160/141/150/9
Pleuritic painRespiratory, thoracic and mediastinal disorders0/32/30/30/31/30/30/6—0/160/140/150/9
VomitingGastrointestinal disorders0/30/30/31/32/31/31/6—1/162/140/150/9
HeadacheNervous system disorders0/30/30/30/30/30/30/6—3/165/142/150/9
EpistaxisRespiratory, thoracic and mediastinal disorders1/30/30/30/30/30/31/6—0/160/140/150/9
Blood pressure increasedInvestigations0/30/31/30/30/30/30/6—0/160/140/150/9
HaemoptysisRespiratory, thoracic and mediastinal disorders0/31/31/30/30/30/32/6—1/161/141/150/9
Herpes ZosterInfections and infestations0/30/30/31/30/30/30/6—0/160/140/150/9

Baseline characteristics

The TSC decided based on the data not to enrol cohort 8.

Age, Continuous
Age, Continuous(years)Stage 1 - Cohort 1 (BTZ 250)Stage 1 - Cohort 2 (BTZ 500)Stage 1 - Cohort 3 (BTZ 750)Stage 1 - Cohort 4 (BTZ 1000)Stage 1 - Cohort 5 (BTZ 1250)Stage 1 - Cohort 6 (BTZ 1500)Stage 1 - Cohort 7 (BTZ 1750)Stage 1 - Cohort 8 (BTZ 2000)Stage 2 - Arm 1 (BTZ High)Stage 2 - Arm 2 (BTZ Medium)Stage 2 - Arm 3 (BTZ Low)Stage 2 - Arm 4 (Control)Total
Mean25.7 ± 3.0645.7 ± 16.336.7 ± 14.427.7 ± 12.427.7 ± 9.0926.3 ± 8.3928.2 ± 6.31—30.5 ± 11.531.7 ± 10.130.2 ± 11.327.2 ± 8.9730.4 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)Stage 1 - Cohort 1 (BTZ 250)Stage 1 - Cohort 2 (BTZ 500)Stage 1 - Cohort 3 (BTZ 750)Stage 1 - Cohort 4 (BTZ 1000)Stage 1 - Cohort 5 (BTZ 1250)Stage 1 - Cohort 6 (BTZ 1500)Stage 1 - Cohort 7 (BTZ 1750)Stage 1 - Cohort 8 (BTZ 2000)Stage 2 - Arm 1 (BTZ High)Stage 2 - Arm 2 (BTZ Medium)Stage 2 - Arm 3 (BTZ Low)Stage 2 - Arm 4 (Control)Total
Female01010010351012
Male3232335013914966
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Stage 1 - Cohort 1 (BTZ 250)Stage 1 - Cohort 2 (BTZ 500)Stage 1 - Cohort 3 (BTZ 750)Stage 1 - Cohort 4 (BTZ 1000)Stage 1 - Cohort 5 (BTZ 1250)Stage 1 - Cohort 6 (BTZ 1500)Stage 1 - Cohort 7 (BTZ 1750)Stage 1 - Cohort 8 (BTZ 2000)Stage 2 - Arm 1 (BTZ High)Stage 2 - Arm 2 (BTZ Medium)Stage 2 - Arm 3 (BTZ Low)Stage 2 - Arm 4 (Control)Total
Black3132015010910751
Other01013210655226
White0100000000001
Not Hispanic or Latino33333360161415978
Region of Enrollment
Region of Enrollment(participants)Stage 1 - Cohort 1 (BTZ 250)Stage 1 - Cohort 2 (BTZ 500)Stage 1 - Cohort 3 (BTZ 750)Stage 1 - Cohort 4 (BTZ 1000)Stage 1 - Cohort 5 (BTZ 1250)Stage 1 - Cohort 6 (BTZ 1500)Stage 1 - Cohort 7 (BTZ 1750)Stage 1 - Cohort 8 (BTZ 2000)Stage 2 - Arm 1 (BTZ High)Stage 2 - Arm 2 (BTZ Medium)Stage 2 - Arm 3 (BTZ Low)Stage 2 - Arm 4 (Control)Total
South Africa3333336—161415978
08

Study locations

2 sites
  • TASK Applied Sciences Clinical Research Centre
    Cape Town, 7530, South Africa
  • University of Cape Town Lung Institute (UCTLI)
    Cape Town, 7700, South Africa
09

References and documents

Publications

  • McClean MCW, Koele SE, Dreisbach J, Mirold-Mei S, Njeleka F, Mapamba D, Mtafya B, Phillips PPJ, De Jager VR, Dawson R, Narunsky K, Diacon AH, Svensson EM, Heinrich N, Casale FP, Hoelscher M. Modeling Treatment Response in Tuberculosis Early Bactericidal Activity Trials. CPT Pharmacometrics Syst Pharmacol. 2026 Aug;15(8):e70311. doi: 10.1002/psp4.70311. PubMed 42568101 ↗
  • Heinrich N, de Jager V, Dreisbach J, Gross-Demel P, Schultz S, Gerbach S, Kloss F, Dawson R, Narunsky K, Matt L, Wildner L, McHugh TD, Fuhr U, Aldana BH, Mouhdad C, Brake LT, Boeree MJ, Aarnoutse RE, Svensson EM, Gong X, P J Phillips P, Diacon AH, Hoelscher M; PanACEA-TB consortium. Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial. Lancet Microbe. 2025 Feb;6(2):100952. doi: 10.1016/j.lanmic.2024.07.015. Epub 2025 Jan 7. PubMed 39793592 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Mar 2022, 27 months.

Results were first posted in Aug 2026, 4 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2019
First posted
Aug 2, 2019
StartActual
Nov 15, 2019
Primary completionActual
Mar 3, 2022
CompletionActual
May 31, 2022
Results first posted
Aug 31, 2026
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04044001
Lead sponsor
Michael Hoelscher
Collaborators
European and Developing Countries Clinical Trials Partnership (EDCTP), Radboud University Medical Center, German Federal Ministry of Education and Research
Responsible party
Michael Hoelscher (Prof. Dr. Michael Hoelscher, Ludwig-Maximilians - University of Munich) — Sponsor-investigator
First posted
Aug 2, 2019
Start date
Nov 15, 2019
Primary completion
Mar 3, 2022
Completion
May 31, 2022
Results posted
Aug 31, 2026
Last update
Aug 31, 2026

Study contacts

Michael Hoelscher, Prof
study director · University Hospital, LMU Munich, Division of Infectious Diseases and Tropical Medicine
Andreas Diacon, Prof
principal investigator · TASK Applied Science Clinical Research Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BTZ-043

Start the discussion